Bachem Holding AG
BANB
Rank in Stocks
#2516
Bachem Holding AG serves pharmaceutical and biotechnology companies globally,... Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.
Share Price
$100.60
Market Cap
$7.54B
Change (1 day)
-1.49%
Change (1 year)
49.53%
Country
CH
Trade Bachem Holding AG (BANB)
Category
Healthcare
P/E ratio for Bachem Holding AG (BANB)
P/E ratio as of October 2026 TTM: 41.76
According to Bachem Holding AG latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 41.76. At the end of 2024 the company had a P/E ratio of 36.10.
P/E ratio history for Bachem Holding AG from 2002 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 41.76 | 38.05% |
| 2025 | 30.25 | -16.21% |
| 2024 | 36.10 | -16.81% |
| 2023 | 43.40 | -25.78% |
| 2022 | 58.48 | -33.90% |
| 2021 | 88.46 | 24.74% |
| 2020 | 70.92 | 79.34% |
| 2019 | 39.54 | 18.49% |
| 2018 | 33.37 | -33.30% |
| 2017 | 50.04 | 68.55% |
| 2016 | 29.69 | 34.57% |
| 2015 | 22.06 | -3.17% |
| 2014 | 22.78 | -17.87% |
| 2013 | 27.74 | -13.45% |
| 2012 | 32.05 | -31.13% |
| 2011 | 46.54 | 74.64% |
| 2010 | 26.65 | 37.59% |
| 2009 | 19.37 | 5.36% |
| 2008 | 18.38 | -7.54% |
| 2007 | 19.88 | -23.58% |
| 2006 | 26.01 | -79.50% |
| 2005 | 126.87 | 374.25% |
| 2004 | 26.75 | 2,864.92% |
| 2003 | 0.90 | 10,771.08% |
| 2002 | 0.01 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -31.08% |
US
|
|
| -28.36 | -167.91% |
US
|
|
| -25.99 | -162.24% |
AU
|
|
| 31.22 | -25.24% |
NL
|
|
| - | - |
CH
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.